Somatostatin signalling and diabetes

The prevalence of diabetes is growing rapidly and currently, over 60 million people worldwide use insulin treatment to manage their diabetes. However, insulin treatment can result in hypoglycemia or low blood sugar levels. To date only retroactive treatments are available to treat hypoglycemia, which affects an individuals quality of life and increases the likelihood of recurring bouts of hypoglycemia as well as development of cardiovascular or renal disease. The goal of this project is to test the efficacy of novel therapeutic targets utilizing somatostatin receptor-2 antagonist and agonists to better manage glycemic control in type 1 diabetics. These pre-clinical studies will set the stage for a human Phase 1 clinical trial. This project is an initial step in improving the treatment of diabetes and the quality of life of patients with diabetes. TO BE CONT”D

Faculty Supervisor:

Michael Riddell

Student:

Erin Mandel-Shorser

Partner:

Centre for Drug Research and Development

Discipline:

Kinesiology

Sector:

Medical devices

University:

Program: